A First-in-Human Study of JNJ-28431754 in Healthy Male Volunteers

This study has been completed.
Sponsor:
Information provided by:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov Identifier:
NCT01177150
First received: August 5, 2010
Last updated: August 10, 2010
Last verified: August 2010
  Purpose

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and or the pharmacodynamics (PD) of single oral doses of JNJ-28431754 in healthy male volunteers. The study will evaluate the PK and PD effects of study drug in volunteers who fasted compared to those who did not fast before study drug administration.


Condition Intervention Phase
Healthy
Drug: JNJ-28431754/ Placebo
Drug: JNJ-28431754
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Escalating Oral Doses of JNJ 28431754 in Healthy Male Subjects

Further study details as provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:

Primary Outcome Measures:
  • Safety and tolerability assessed by evaluating adverse events reported and results from vital signs measurements, electrocardiograms, physical examinations performed and laboratory tests. [ Time Frame: From Screening (within 21 days prior to Day 1) up to Day 14 or at the time of early withdrawal ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Urine Glucose Excretion (the amount of glucose excreted in the urine per 24 hours and the amount of glucose excreted in each urine collection fraction) [ Time Frame: At protocol-specified timepoints before and after study drug administration on Day 1 ] [ Designated as safety issue: No ]
  • The renal threshold for Urinary Glucose Excretion [ Time Frame: At protocol-specified timepoints before and after study drug administration on Day 1 ] [ Designated as safety issue: No ]
  • Plasma glucose, serum insulin and serum C peptide concentrations measured from blood samples collected [ Time Frame: At protocol-specified timepoints before and after study drug administration on Day 1 ] [ Designated as safety issue: No ]

Enrollment: 71
Study Start Date: November 2006
Study Completion Date: April 2007
Primary Completion Date: April 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 001
JNJ-28431754/ Placebo Part 1: One oral dose of JNJ 28431754 (10 mg to 600 mg) or matching placebo will be administered after an overnight fast of at least 10 hours .For patients who receive a previously tested dose as 2 equally divided doses the evening dose will be administered at 10 hours after the morning dose.
Drug: JNJ-28431754/ Placebo
Part 1: One oral dose of JNJ 28431754 (10 mg to 600 mg) or matching placebo will be administered after an overnight fast of at least 10 hours .For patients who receive a previously tested dose as 2 equally divided doses, the evening dose will be administered at 10 hours after the morning dose.
Experimental: 002
JNJ-28431754 Part 2: A single dose of JNJ-28431754 will be orally administered on 2 occasions (14 days apart) after an overnight fast of at least 10 hours with and without a standard meal.
Drug: JNJ-28431754
Part 2: A single dose of JNJ-28431754 will be orally administered on 2 occasions (14 days apart) after an overnight fast of at least 10 hours with and without a standard meal.

Detailed Description:

This is a single-center study that will be conducted in two Parts (Part 1 and Part 2). Volunteers may participate in Part 1 or Part 2 of the study but not in both Part 1 and Part 2. Part 1 of the study will evaluate the safety and tolerability of single, oral (by mouth) escalating (increasing) doses of JNJ 28431754 (ranging from 10 mg to 600 mg) or placebo in healthy male volunteers. The pharmacokinetics (PK), how JNJ 28431754 is absorbed, distributed, and removed from the body over time and pharmacodynamics (PD), the effects JNJ-28431754 has on the body, will also be evaluated. Part 2 of the study is a randomized, 2 period crossover study where 8 eligible male volunteers will receive a single oral dose of JNJ 28431754 on 2 occasions (14 days apart) with and without food (ie, a standard meal) to assess the effect of co-administration with food on the PK and PD of JNJ-28431754. In Part 1, at least 48 healthy male volunteers who meet entry criteria will be randomized (assigned by chance) into 6 cohorts (dose groups) and receive a single oral dose of study drug (JNJ-28431754 or placebo); study drug will be assigned to volunteers double-blinded (neither the investigator or the volunteer will know the identity of the assigned treatment). One or more additional cohorts may be added to the study; the additional cohort may test a previously tested dose of JNJ 28431754 as 2 equally divided doses, to be administered 10 hours apart. Each volunteer will participate in one dose group only. Each dose group will evaluate a different dose strength of JNJ-28431754 (10 mg to 600 mg) starting at the lowest dose. Volunteers in each dose group will be required to stay overnight in the clinical research unit (CRU) for 6 nights to receive study drug and to have safety, tolerability, PK, and PD assessments performed. Patients will return to the CRU for a final safety follow-up visit 10 to 14 days after study drug administration. For each volunteer, the total duration of Part 1 of the study will be at least 5 weeks (includes a 3-week screening period). In Part 2 of the study, 8 eligible male volunteers will receive a single oral dose of JNJ 28431754 on 2 occasions (14 days apart) with and without food (ie, a standard meal); JNJ-28431754 will be administered to volunteers as "open-label" treatment (ie, volunteers will know that they are receiving active drug) . Part 2 will begin after sufficient data has been collected from Part 1 to select the dose of JNJ-28431754 for Part 2 of the study (the dose selected will be within the dose range evaluated in Part 1 of the study). Volunteers will be required to stay overnight in the CRU for 5 nights on 2 occasions to receive study drug and to have post dose safety, tolerability, PK, and PD assessments performed. Patients will return to the CRU for a final safety follow-up visit 10 to 14 days after the 2nd single-dose administration of JNJ-38431754. For each volunteer, the total duration of Part 2 of the study will be approximately 7 weeks (includes a 3-week screening period and about a 2-week interval between the 2 single-dose administrations of JNJ 38431754). Volunteers in Part 1 and Part 2 of the study will be monitored for safety during the study by evaluating adverse events reported and results from vital signs measurements, electrocardiograms, physical examinations performed and laboratory tests. Part 1: One dose of JNJ-28431754 (10mg to 600mg) or placebo will be administered after an overnight fast of at least 10 hours (for additional cohorts, previously tested doses will be administered as 2 equally divided doses taken 10 hours apart). Part 2: One dose of JNJ-28431754 will be administered on 2 occasions (14 days apart) after an overnight fast of at least 10 hours with and without a standard meal. All doses of study drug will be administered to patients orally using an oral dispenser.

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Have body mass index (BMI) between 20.0 and 29.9 kg/m2 inclusive
  • Be a non-smoker or non-tobacco user (not smoked cigarettes or used tobacco-containing products for at least 6 months prior to screening)
  • Have competency in speaking and comprehending the language where the study will be conducted

Exclusion Criteria:

  • Have history, or family history of bleeding or coagulation disorders or history of disorders that are potential causes of occult (test positive for fecal blood test without visible blood in feces) gastrointestinal bleeding
  • Have currently active skin disorders
  • Have history of renal or urinary tract diseases
  • Have history of having chronically taken (daily administration for more than 7 days) oral steroids, topical iodine, aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), anticoagulants or other drugs known to interfere with blood clotting within 3 months of study start, or anticipates a need to take any of these during the course of the study
  • Have history of recent major surgery (within 6 months of study start)
  • Have history of recent travel (within 6 months) to locations that may predispose to the acquisition of communicable illnesses (e.g., parasitic or water-borne illnesses in developing tropical regions)
  • Have recent history of alcohol or drug abuse within 6 months prior to screening
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01177150

Sponsors and Collaborators
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Investigators
Study Director: Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
  More Information

No publications provided

Responsible Party: Study Physician, Johnson & Johnson Pharmaceutical Research and Development, L.L.C.
ClinicalTrials.gov Identifier: NCT01177150     History of Changes
Other Study ID Numbers: CR012454, 28431754NAP1001
Study First Received: August 5, 2010
Last Updated: August 10, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:
Sodium-Glucose Transporter 2
Canagliflozin
Pharmacodynamic
Pharmacokinetic
Safety
Tolerability

ClinicalTrials.gov processed this record on September 18, 2014